Contact Us
Drug Search Results
Using advanced filters...
Advanced Search [+]

Selurampanel

Alternative Names: selurampanel, bgg-492, bgg492, bgg 492, BGG492A
Latest Update: 2022-12-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: KAR Antagonist,AMPA Antagonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Seizures|Adrenocortical Adenoma|Epilepsy|Migraine Disorders|Epilepsy, Reflex|Sarcoma, Endometrial Stromal|Migraine without Aura|Migraine with Aura|Tinnitus|Muscle Spasticity|Multiple Sclerosis|Adenoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
2006-7041-83/hah

N/A

Not yet recruiting

Depressive Disorder

2021-05-28

CBGG492A2215

P2

Withdrawn

Multiple Sclerosis|Muscle Spasticity

2018-03-01

CBGG492A2214

P2

Withdrawn

Migraine Disorders

2016-11-01

2013-003431-29

P2

Completed

Adenoma

2015-09-21

CBGG492A2216

P2

Completed

Adrenocortical Adenoma|Sarcoma, Endometrial Stromal

2015-09-01

2011-005316-28

P2

Terminated

Migraine Disorders|Migraine without Aura|Migraine with Aura

2013-04-05

2010-021448-17

P2

Completed

Epilepsy

2012-07-04

CBGG492A2212

P2

Completed

Seizures

2012-07-01

2010-022166-27

P2

Completed

Tinnitus

2012-01-31

CBGG492A2210

P2

Completed

Tinnitus

2012-01-01

2009-017961-52

P2

Completed

Seizures

2011-09-26

CBGG492A2207

P2

Completed

Seizures

2011-09-01

2010-018766-23

P2

Terminated

Unknown

2010-11-08

CBGG492A2211

P2

Withdrawn

Seizures

2010-11-01

CBGG492A2203

P2

Completed

Epilepsy, Reflex

2010-09-01

2008-005392-10

P2

Completed

Migraine Disorders

2010-08-24

2008-005065-64

P2

Completed

Epilepsy

2010-08-05

CBGG492A2204

P2

Completed

Migraine Disorders

2010-08-01

CBGG492A2202

P2

Completed

Epilepsy

2010-08-01

Recent News Events

Date

Type

Title

12/01/2022

PubMed

 Current and future pharmacotherapy options for drug-resistant epilepsy.

01/01/2021

PubMed

 Efficacy and safety of single- and repeated-selurampanel dosing for 2 weeks in patients with chronic subjective tinnitus: Results of a randomized, double-blind, placebo-controlled, cross-over, proof-of-concept phase IIa study.

10/18/2019

News Article

 Global Tinnitus Pipeline Insights 2019

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions